Biological agents for chronic wounds

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Tumor necrosis factor alpha antagonists (e.g. etanercept) are now being extensively evaluated in the setting of chronic wound healing. Preliminary studies and case reports provide evidence of the clinical potential of these compounds in pyoderma gangrenosum, and further investigations are warranted. A clear rationale also exists for further detailed assessments of the potential efficacy of etanercept in patients with venous leg ulcers or hospital-acquired pressure ulcers.

Original languageEnglish
Pages (from-to)23-25
Number of pages3
JournalAmerican Journal of Clinical Dermatology
Volume11
Issue numberSUPPL. 1
DOIs
StatePublished - Jul 9 2010

Fingerprint

Biological Factors
Pyoderma Gangrenosum
Varicose Ulcer
Leg Ulcer
Pressure Ulcer
Wounds and Injuries
Wound Healing
Tumor Necrosis Factor-alpha
Etanercept

ASJC Scopus subject areas

  • Dermatology

Cite this

Biological agents for chronic wounds. / Kirsner, Robert.

In: American Journal of Clinical Dermatology, Vol. 11, No. SUPPL. 1, 09.07.2010, p. 23-25.

Research output: Contribution to journalArticle

@article{84bfd38e25d442e0ab878c833cf52c5b,
title = "Biological agents for chronic wounds",
abstract = "Tumor necrosis factor alpha antagonists (e.g. etanercept) are now being extensively evaluated in the setting of chronic wound healing. Preliminary studies and case reports provide evidence of the clinical potential of these compounds in pyoderma gangrenosum, and further investigations are warranted. A clear rationale also exists for further detailed assessments of the potential efficacy of etanercept in patients with venous leg ulcers or hospital-acquired pressure ulcers.",
author = "Robert Kirsner",
year = "2010",
month = "7",
day = "9",
doi = "10.2165/1153417-S0-000000000-00000",
language = "English",
volume = "11",
pages = "23--25",
journal = "American Journal of Clinical Dermatology",
issn = "1175-0561",
publisher = "Adis International Ltd",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Biological agents for chronic wounds

AU - Kirsner, Robert

PY - 2010/7/9

Y1 - 2010/7/9

N2 - Tumor necrosis factor alpha antagonists (e.g. etanercept) are now being extensively evaluated in the setting of chronic wound healing. Preliminary studies and case reports provide evidence of the clinical potential of these compounds in pyoderma gangrenosum, and further investigations are warranted. A clear rationale also exists for further detailed assessments of the potential efficacy of etanercept in patients with venous leg ulcers or hospital-acquired pressure ulcers.

AB - Tumor necrosis factor alpha antagonists (e.g. etanercept) are now being extensively evaluated in the setting of chronic wound healing. Preliminary studies and case reports provide evidence of the clinical potential of these compounds in pyoderma gangrenosum, and further investigations are warranted. A clear rationale also exists for further detailed assessments of the potential efficacy of etanercept in patients with venous leg ulcers or hospital-acquired pressure ulcers.

UR - http://www.scopus.com/inward/record.url?scp=77954276699&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954276699&partnerID=8YFLogxK

U2 - 10.2165/1153417-S0-000000000-00000

DO - 10.2165/1153417-S0-000000000-00000

M3 - Article

C2 - 20586502

AN - SCOPUS:77954276699

VL - 11

SP - 23

EP - 25

JO - American Journal of Clinical Dermatology

JF - American Journal of Clinical Dermatology

SN - 1175-0561

IS - SUPPL. 1

ER -